Edition:
United Kingdom

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,799.50GBp
21 Feb 2018
Change (% chg)

77.50 (+1.64%)
Prev Close
4,722.00
Open
4,717.00
Day's High
4,815.00
Day's Low
4,699.00
Volume
2,086,261
Avg. Vol
2,284,050
52-wk High
5,585.07
52-wk Low
4,260.00

Chart for

About

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in... (more)

Overall

Beta: 1.04
Market Cap(Mil.): £65,514.78
Shares Outstanding(Mil.): 1,265.91
Dividend: 68.90
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

U.S. health officials reverse stance on AstraZeneca's flu vaccine

AstraZeneca Plc said on Wednesday an advisory committee of the U.S. Centers for Disease Control and Prevention recommended the use of its FluMist Quadrivalent vaccine in the upcoming flu season, reversing its earlier position.

21 Feb 2018

U.S. health officials reverse stance on AstraZeneca's flu vaccine

AstraZeneca Plc said on Wednesday an advisory committee of the U.S. Centers for Disease Control and Prevention recommended the use of its FluMist Quadrivalent vaccine in the upcoming flu season, reversing its earlier position.

21 Feb 2018

U.S. health officials reverse stance on AstraZeneca's flu vaccine

Feb 21 AstraZeneca Plc said on Wednesday an advisory committee of the U.S. Centers for Disease Control and Prevention recommended the use of its FluMist Quadrivalent vaccine in the upcoming flu season, reversing its earlier position.

21 Feb 2018

BRIEF-Astrazeneca Announces Renewed U.S. Recommendation, Availability Of Flumist Quadrivalent Vaccine

* ASTRAZENECA ANNOUNCES RENEWED RECOMMENDATION AND AVAILABILITY OF FLUMIST QUADRIVALENT VACCINE IN THE US

21 Feb 2018

BRIEF-Ionis Licences New Antisense Drug For Kidney Disease To Astrazeneca

* IONIS LICENCES NEW ANTISENSE DRUG FOR KIDNEY DISEASE TO ASTRAZENECA

20 Feb 2018

AstraZeneca's immunotherapy drug wins key lung cancer approval

LONDON AstraZeneca's immunotherapy drug Imfinzi has won crucial approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors.

19 Feb 2018

AstraZeneca's immunotherapy drug wins key lung cancer approval

LONDON AstraZeneca's immunotherapy drug Imfinzi has won crucial approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors.

19 Feb 2018

UPDATE 2-AstraZeneca's immunotherapy drug wins key lung cancer approval

* Rival BMS, Merck, Roche drugs approved for later disease (Adds shares, analyst reaction)

19 Feb 2018

BRIEF-AstraZeneca ‍Says US FDA Approves Imfinzi For Unresectable Stage III Non-Small Cell Lung Cancer​

* ‍US FDA APPROVES IMFINZI FOR UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER​

19 Feb 2018

U.S. FDA approves AstraZeneca's immunotherapy for lung cancer

The U.S. Food and Drug Administration on Friday granted approval for expanded use of AstraZeneca Plc's , immunotherapy drug, Imfinzi, to treat non-small cell lung cancer whose tumours can't be surgically removed.

16 Feb 2018

Earnings vs. Estimates